IndustryCompany release

Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial

🇺🇸 Cerenome, Inc. (CNSY) · Fri 13 Nov 2026

The company formerly known as Plus Therapeutics posted $0.7M in diagnostic revenue for Q3 2026, added Aetna coverage and reported clean early safety data for REYOBIQ.

Cerenome, Inc., formerly Plus Therapeutics, reported third-quarter 2026 results on 13 November. Net revenue from its CNSide diagnostic was $0.7M, the first revenue the company has reported from the product. The quarter's net loss was $8.7M, and cash stood at $4.9M.

On market access, Cerenome added payer agreements, including one with Aetna. Contracted coverage now reaches about 190M lives. The company expects Medicare reimbursement for CNSide in the first half of 2027.

In the clinic, interim Phase 1 ReSPECT-LM data for REYOBIQ in leptomeningeal metastases showed no dose-limiting toxicities in the first 10 patients. The summary does not give dosing details or efficacy findings, and the interim dataset is small.

Enrolment is also complete in the Phase 2 trial of REYOBIQ in recurrent glioblastoma. Cerenome expects topline data in mid-2027.

What it means for your team

  • Market-access teams can track CNSide as an example of a diagnostic building commercial payer contracts ahead of expected Medicare reimbursement in the first half of 2027.
  • Safety and pharmacovigilance teams should note that the interim REYOBIQ result, no dose-limiting toxicities in 10 patients, comes from an early, small cohort and is not a full safety profile.
  • Regulatory watchers have two dates to follow: the Medicare reimbursement expected in H1 2027 and the topline glioblastoma data expected mid-2027.
  • The $4.9M cash balance against an $8.7M quarterly loss is a financial detail relevant to partners and counterparties assessing the company.

Company's press release (SEC filing): Cerenome, Inc. ↗

Article written by VigiEye from the official source (Cerenome, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →